Oryzon Genomics S.A.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oryzon Genomics S.A.
Public Company Edition: Two months before the deadline for the company's sNDA, the US FDA has not indicated it will hold an advisory committee meeting for the triglyceride-lowering drug. Also, Seattle Genetics raises $575m, Atara and Ra bring in $150m each and Cara completes $145.5m offering.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced September and October 2018.
After the setback of Roche pulling the plug on a potentially lucrative cancer partnership last year, the Spanish biotech tells Scrip it has bounced back with a compound that shows potential in Alzheimer's, multiple sclerosis and other neurodegenerative and psychiatric diseases.
Start-ups in Spain will descend on the Andalusian city next week for the BioSpain meeting in search of national and international investors and collaborators to boost their respective R&D pipelines.
Drug Discovery Tools
- Drug Discovery Tools